Fundraising Fox
/Companies
Sign in

Agendia

Irvine, US · Founded 2003 · 224 employees on LinkedIn · 8 known investors

Find your way into Agendia

Sign up to see every warm intro you have to Agendia

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Agendia team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Agendia develops genomic technology and diagnostic tests for breast cancer patients. The company applies genomic science to improve treatment outcomes and quality of life for cancer patients.

AI & Machine LearningBiotechDigital HealthMedical Devices

Founders & leadership

Agendia was founded in 2003 by Laura van 't Veer, René Bernards, Prof. Laura van 't Veer, PhD, and Prof. Dr. René Bernards, PhD.

LVLaura van 't Veer
Laura van 't VeerCo-founderLaura van 't Veer is a molecular biologist and co-founder of Agendia who developed genomic diagnostic approaches for breast cancer treatment. Her research has examined tumor genetic profiling to guide treatment decisions, including leadership of the MINDACT clinical trial and work on the MammaPrint test now incorporated into major clinical guidelines.
RBRené Bernards
René BernardsCo-founderRené Bernards holds a Ph.D. from the University of Leiden and trained at the Whitehead Institute under Robert Weinberg, studying oncogenes and tumor suppressor genes before holding faculty positions at Massachusetts General Hospital and Utrecht University and senior scientist roles at the Netherlands Cancer Institute. He co-founded Agendia in 2003, a genomics-based diagnostic company that developed the first microarray-based breast cancer diagnostic test, and his research has focused on genome-wide functional genetic screens to identify biomarkers of cancer drug response.
PL
Prof. Laura van 't Veer, PhDChief Research Officer, Co-founder
PDProf. Dr. René Bernards, PhD
Prof. Dr. René Bernards, PhDCo-Founder and Scientific Advisor
MRMark R. Straley
Mark R. StraleyCEO

Investors · 8

ForbionreportedNaarden

How we know: a partner's Signal profile · Not right? Tell us

Gilde HealthcarereportedUtrecht · $1.1M – $55M

How we know: funding news · prnewswire.com · Not right? Tell us

Also in the syndicate · 5

Athyrium Capital ManagementBreedinvestDebiopharm GroupleadING Corporate InvestmentsThe Van Herk Group

Founder mafia

3 people who came through Agendia went on to found or lead other companies.

Bastiaan van der BaanVP Marketing and SalesFounded Lixte Biotechnology HoldingsLaurie HeilmannMember of The Supervisory Board of DirectorsFounded NotableRuby GadelrabCommercialization Strategy ConsultantFounded MDisrupt

In the news

Agendia Secures $35 Million Investment from Funds Managed by Athyrium Capital Management to Support Expanded Commercial Footprint in Rapidly Growing Markets and New Research Collaborations - Agendiaagendia.com · Jul 2018Agendia Raises $65 Million in a Private Round of Equity Financingprnewswire.com · May 2012

Frequently asked questions

What does Agendia do?
Agendia develops genomic technology and diagnostic tests for breast cancer patients. The company applies genomic science to improve treatment outcomes and quality of life for cancer patients.
Who founded Agendia?
Agendia was founded by Laura van 't Veer, René Bernards, Prof. Laura van 't Veer, PhD, Prof. Dr. René Bernards, PhD in 2003.
Who are Agendia's investors?
Agendia's investors include Korys, Forbion, Gilde Healthcare.
Where is Agendia headquartered?
Agendia is headquartered in Irvine, US.